SJ000291942 is a bone morphogenic protein (BMP) signaling activator. SJ000291942 causes an increase in bmp2b and szl expression. Zebrafish assays suggest that SJ000291942 activates the canonical BMP signaling pathway. To extend these observations, immunoblotting of protein lysates from C33A-2D2 cells stimulated with SJ000291942 at different times is performed. SJ000291942 activates phosphorylation of SMAD1/5/8 in serum-free medium. Like in zebrafish embryos, SJ000291942 is most active. SJ000291942 induces p-SMAD1/5/8 maximally at 1hr of treatment. Immunoblotting analysis of lysates from C33A-2D2 treated with SJ000291942 reveals clear induction of the phosphorylated Extracellular Signal-regulated protein Kinase, ERK1/2 (P-ERK1/2) by SJ000291942.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Solubility||DMSO ≥ 90 mg/mL|
|Related TGF-beta/Smad Products|
BIBF0775 is a potent and selective inhibitor of the transforming growth factor β receptor I (TGFβRI, Alk5) with an IC50 of 34 nM.
SB-4 is a potent benzoxazole bone morphogenetic protein 4 (BMP4) signaling agonist with a EC50 value of 74 nM.
SM16 inhibits TGFβ-induced plasminogen activator inhibitor-luciferase activity (IC50=64 nM).
SRI-011381 is an agonist of the TGF-beta signaling pathway for treatment of Alzheimer's disease.
ITD-1 is a selective inhibitor of TGF-β signaling (IC50 ~ 0.4-0.8 μM).
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.